Showing 1821-1830 of 2123 results for "".
- New Tablet Formulation of Evrysdi for Spinal Muscular Atrophy Greenlighted by the FDAhttps://practicalneurology.com/news/new-tablet-formulation-of-evrysdi-for-spinal-muscular-atrophy-greenlighted-by-the-fda/2473784/A New Drug Application (NDA) for a tablet formulation of Evrysdi (risdiplam; Genentech, South San Francisco, CA) has been approved by the Food and Drug Administration (FDA) for the treatment of participants aged ≥2 years with spinal muscular atrophy (SMA) who weigh ≥20 kg. Evrysdi was first
- Anaphylaxis Boxed Warning Added to MS Medication Labelhttps://practicalneurology.com/news/anaphylaxis-boxed-warning-added-to-ms-medication-label/2473770/The Food and Drug Administration (FDA) has added a Boxed Warning to the prescribing information of glatiramer acetate, a medication for multiple sclerosis (MS) sold under the brand name Copaxone (glatiramer acetate injection; Teva, Tel Aviv-Yafo, Israel) and the generic name Glatopa (glatiramer a
- Hypertensive Pregnancies Linked to Increased Risk of Neurologic Conditionshttps://practicalneurology.com/news/hypertensive-pregnancies-linked-to-increased-risk-of-neurological-conditions/2470945/A Swedish register-based cohort study, published in JAMA Neurology, has found that women who experience gestational hypertension, preeclampsia, or eclampsia during pregnancy face an elevated risk of developing neurologic disorders in the months to years following childbirth, including mi
- Warning for Guillain-Barré Syndrome Added to the Labels of 2 RSV Vaccineshttps://practicalneurology.com/news/warning-for-guillain-barre-syndrome-added-to-the-labels-of-2-rsv-vaccines/2470942/The prescribing information for the vaccines Abrysvo (respiratory syncytial virus vaccine; Pfizer, New York, NY) and Arexvy (respiratory syncytial virus vaccine, adjuvanted; GSK, London, United Kingdom) has been updated to include new warnings for the risk of Guillain-Barré syndrome (GBS).
- Frailty Linked to Greater Risk of Dementiahttps://practicalneurology.com/news/frailty-linked-to-greater-risk-of-dementia/2470643/Frailty measurements may enable the identification of individuals at higher risk of dementia up to 9 years before the onset of the disorder, according to study results published in JAMA Neurology. According to the study authors, the findings demonstrate the potential utility of frailty m
- Children with Migraine Can Now Receive Neuromodulatory Treatment with the Nerivio REN Devicehttps://practicalneurology.com/news/children-with-migraine-can-now-receive-neuromodulatory-treatment-with-the-nerivio-device-1/2470639/The Food and Drug Administration (FDA) has expanded the age indication for Nerivio (Theranica, Bridgewater Township, NJ), making it the first non-drug therapy and prescribed preventive treatment for children with migraine aged ≥8 years. Nerivio is a remote electrical neuromodulation (REN) devi
- Favorable Results for Radiprodil Tx for GRIN Disorders Leads to Launch of Study to Test Treatment in Those with Tuberous Sclerosis or Focal Cortical Dysplasiahttps://practicalneurology.com/news/favorable-results-for-radiprodil-tx-for-grin-disorders-leads-to-launch-of-study-to-test-treatment-in-those-with-tuberous-sclerosis-or-focal-cortical-dysplasia/2470617/Treatment with radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), was well tolerated and associated with a significant reduction in seizure frequency in children with GRIN-related neurod
- Alzheimer's Drug Discovery Foundation Announces Development of Comprehensive Biomarker Observatoryhttps://practicalneurology.com/news/alzheimers-drug-discovery-foundation-announces-development-of-comprehensive-biomarker-observatory/2470602/The Alzheimer’s Drug Discovery Foundation (ADDF; New York, NY) announced the investment of $3.2 million to the University of Nevada Las Vegas (UNLV) to develop the first ever Biomarker Observatory for Alzheimer disease (AD). The Biomarker Observatory is designed to record and categorize inf
- Study Compares FUS Unilateral Thalamotomy vs FUS Subthalamotomy in People with Medication Refractory Tremorhttps://practicalneurology.com/news/study-compares-fus-unilateral-thalamotomy-vs-fus-subthalamotomy-in-people-with-medication-refractory-tremor/2470600/Research presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders compared the effects of unilateral focused ultrasound subthalamotomy (FUS-STN) with unilateral focused ultrasound of the ventral intermediate thalamic nucleus (FUS-Vim) in participants with m
- FDA Greenlights First Treatment for Niemann-Pick Disease Type Chttps://practicalneurology.com/news/fda-greenlights-first-treatment-for-niemann-pick-disease-type-c/2470589/The Food and Drug Administration (FDA) has approved Miplyffa (arimoclomol; Zevra Therapeutics, Celebration, FL) for use in combination with miglustat for the treatment of neurologic manifestations of Niemann-Pick disease type C (NPC) for adult and pediatric patients aged ≥2 years. Miplyffa is